Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA PDT for Oral Leukoplakia
NCT00571974Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Jan 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 5-aminolevulinic acid in oral leukoplakia and erythroplakia, sponsored by University of Arkansas. Primary endpoint: Maximum Tolerated Dose at 2 days. Started Jan 2007; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
oral leukoplakiaerythroplakia
Beyond the preview
Go deeper on NCT00571974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571974.